{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:43:32Z","timestamp":1783543412083,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi del Piemonte Orientale Amedeo Avogrado"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>Pleural mesothelioma (PM) is a rare cancer affecting the pleural layer on the body\u2019s serosal surfaces. Exposure to asbestos fibers, a naturally occurring fibrous material with insulating characteristics, contributes to PM\u2019s prevalence. PM has a long latency period, making major surgery ineffective and necessitating systemic treatment. Despite the progress of mesothelioma treatment, the median survival is very poor; so, there is a strong need to explore new therapeutic approaches. This study explores the use of BOLD-100, a novel therapeutic drug that targets GRP78, a protein overexpressed in PM cells. BOLD-100, a ruthenium-based small molecule therapeutic drug, is being investigated for the treatment of advanced gastrointestinal malignancies in conjunction with chemotherapy. Our aim is to investigate cellular responses of several PM cell lines to a regimen that includes BOLD-100 in addition to other commonly used treatments. BOLD-100 is a ruthenium-based anticancer therapeutic.<\/jats:p>","DOI":"10.1007\/s10637-025-01540-9","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T05:36:30Z","timestamp":1746682590000},"page":"634-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-5763","authenticated-orcid":false,"given":"Gregorio","family":"Bonsignore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7600-8215","authenticated-orcid":false,"given":"Elia","family":"Ranzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2891-1810","authenticated-orcid":false,"given":"Simona","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"1540_CR1","doi-asserted-by":"publisher","unstructured":"Duncan LT (2021) Advances in health and disease, vol 44. Nova Publishers Inc., Hauppauge, New York. https:\/\/doi.org\/10.52305\/FRKL1404","DOI":"10.52305\/FRKL1404"},{"issue":"4","key":"1540_CR2","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3978\/j.issn.2225-319X.2012.11.03","volume":"1","author":"C Cao","year":"2012","unstructured":"Cao C, Croce B, Harris R (2012) MPM: malignant pleural mesothelioma. Ann Cardiothorac Surg 1(4):544. https:\/\/doi.org\/10.3978\/j.issn.2225-319X.2012.11.03","journal-title":"Ann Cardiothorac Surg"},{"issue":"7","key":"1540_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","volume":"3","author":"A Santoro","year":"2008","unstructured":"Santoro A, O\u2019Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M et al (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 3(7):756\u2013763. https:\/\/doi.org\/10.1097\/JTO.0b013e31817c73d6","journal-title":"J Thorac Oncol"},{"issue":"10272","key":"1540_CR4","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397(10272):375\u2013386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"issue":"10","key":"1540_CR5","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.1002\/jcp.26631","volume":"233","author":"S Martinotti","year":"2018","unstructured":"Martinotti S, Ranzato E, Burlando B (2018) (-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress. J Cell Physiol 233(10):7082\u20137090. https:\/\/doi.org\/10.1002\/jcp.26631","journal-title":"J Cell Physiol"},{"key":"1540_CR6","doi-asserted-by":"publisher","unstructured":"Ranzato E, Bonsignore G, Martinotti S (2022) ER Stress response and induction of apoptosis in malignant pleural mesothelioma: the achilles heel targeted by the anticancer ruthenium drug BOLD-100. Cancers (Basel) 14(17). https:\/\/doi.org\/10.3390\/cancers14174126","DOI":"10.3390\/cancers14174126"},{"key":"1540_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jprot.2016.02.021","volume":"145","author":"M Manfredi","year":"2016","unstructured":"Manfredi M, Martinotti S, Gosetti F, Ranzato E, Marengo E (2016) The secretome signature of malignant mesothelioma cell lines. J Proteomics 145:3\u201310. https:\/\/doi.org\/10.1016\/j.jprot.2016.02.021","journal-title":"J Proteomics"},{"issue":"6","key":"1540_CR8","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/bjc.2013.66","volume":"108","author":"LE Dalton","year":"2013","unstructured":"Dalton LE, Clarke HJ, Knight J, Lawson MH, Wason J, Lomas DA et al (2013) The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer 108(6):1340\u20131347. https:\/\/doi.org\/10.1038\/bjc.2013.66","journal-title":"Br J Cancer"},{"issue":"6","key":"1540_CR9","doi-asserted-by":"publisher","first-page":"e000154","DOI":"10.1136\/esmoopen-2016-000154","volume":"1","author":"HA Burris","year":"2016","unstructured":"Burris HA, Bakewell S, Bendell JC, Infante J, Jones SF, Spigel DR et al (2016) Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. ESMO Open 1(6):e000154. https:\/\/doi.org\/10.1136\/esmoopen-2016-000154","journal-title":"ESMO Open"},{"key":"1540_CR10","doi-asserted-by":"publisher","unstructured":"Griffin D, Carson R, Moss D, Sessler T, Lavin D, Tiwari VK et al (2024) Ruthenium drug BOLD-100 regulates BRAFMT colorectal cancer cell apoptosis through AhR\/ROS\/ATR signaling axis modulation. Mol Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-24-0151","DOI":"10.1158\/1541-7786.MCR-24-0151"},{"key":"1540_CR11","doi-asserted-by":"publisher","unstructured":"Spratlin JL, O\u2019Kane G, Goodwin RA, McWhirter E, Thompson D, Halani K et al (2022) BOLD-100\u2013001 (TRIO039): a phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: interim safety, tolerability, and efficacy. J Clin Oncol 40(16). https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.303","DOI":"10.1200\/JCO.2022.40.16_suppl.303"},{"key":"1540_CR12","doi-asserted-by":"publisher","unstructured":"O\u2019Kane GM, Spratlin JL, Oh D-Y, Rha SY, Elimova E, Kavan P et al (2023) BOLD-100-001 (TRIO039): a phase 1b\/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: efficacy and safety analysis. J Clin Oncol 41(16_suppl).\u00a0https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4098","DOI":"10.1200\/JCO.2023.41.16_suppl.4098"},{"key":"1540_CR13","doi-asserted-by":"publisher","unstructured":"O\u2019Kane GM, Oh D-Y, Spratlin J, Rha SY, Elimova E et al (2024) A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: efficacy and safety analysis (BOLD-100\u2013001). J Clin Oncol 42. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4115","DOI":"10.1200\/JCO.2024.42.16_suppl.4115"},{"key":"1540_CR14","doi-asserted-by":"publisher","unstructured":"Spratlin JL, O\u2019Kane GM, Oh D-Y, Rha SY, McWhirter E, Elimova E et al (2024) A phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX\/CAPOX\u2014efficacy and safety analysis. J Clin Oncol 43. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.143","DOI":"10.1200\/JCO.2024.42.3_suppl.143"},{"issue":"2","key":"1540_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00428-022-03321-8","volume":"481","author":"F Napoli","year":"2022","unstructured":"Napoli F, Rapa I, Izzo S, Rigutto A, Libener R, Riganti C et al (2022) Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. Virchows Arch 481(2):233\u2013244. https:\/\/doi.org\/10.1007\/s00428-022-03321-8","journal-title":"Virchows Arch"},{"key":"1540_CR16","doi-asserted-by":"publisher","unstructured":"Bonvicini P, Libener R, Amore V, Oliveri G, Maconi A (2022) Alessandria Biobank: origins, evolution and future scenarios. Work Pap Public Health 10(1). https:\/\/doi.org\/10.4081\/wpph.2022.9522","DOI":"10.4081\/wpph.2022.9522"},{"issue":"11","key":"1540_CR17","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1111\/j.1582-4934.2012.01584.x","volume":"16","author":"E Ranzato","year":"2012","unstructured":"Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, Mutti L et al (2012) Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening. J Cell Mol Med 16(11):2667\u20132678. https:\/\/doi.org\/10.1111\/j.1582-4934.2012.01584.x","journal-title":"J Cell Mol Med"},{"key":"1540_CR18","doi-asserted-by":"publisher","unstructured":"Pellavio G, Martinotti S, Patrone M, Ranzato E, Laforenza U (2022) Aquaporin-6 may increase the resistance to oxidative stress of malignant pleural mesothelioma cells. Cells 11(12). https:\/\/doi.org\/10.3390\/cells11121892","DOI":"10.3390\/cells11121892"},{"key":"1540_CR19","doi-asserted-by":"publisher","unstructured":"Lombardo T, Anaya A, Kornblihtt L, Blanco G (2012) Median effect dose and combination index analysis of cytotoxic drugs using flow cytometry. In: Schmid I (ed) Flow cytometry - recent perspectives. IntechOpen. London, pp\u00a0393\u2013420. https:\/\/doi.org\/10.5772\/38214","DOI":"10.5772\/38214"},{"issue":"11","key":"1540_CR20","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1080\/10428190802353591","volume":"49","author":"TC Chou","year":"2008","unstructured":"Chou TC (2008) Preclinical versus clinical drug combination studies. Leuk Lymphoma 49(11):2059\u20132080. https:\/\/doi.org\/10.1080\/10428190802353591","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1540_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"key":"1540_CR22","doi-asserted-by":"publisher","unstructured":"Bakewell S, Conde I, Fallah Y, McCoy M, Jin L, Shajahan-Haq AN (2020) Inhibition of DNA repair pathways and induction of ROS are potential mechanisms of action of the small molecule inhibitor BOLD-100 in breast cancer. Cancers (Basel) 12(9). https:\/\/doi.org\/10.3390\/cancers12092647","DOI":"10.3390\/cancers12092647"},{"issue":"10","key":"1540_CR23","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1002\/anie.202015962","volume":"60","author":"B Neuditschko","year":"2021","unstructured":"Neuditschko B, Legin AA, Baier D, Schintlmeister A, Reipert S, Wagner M et al (2021) Interaction with ribosomal proteins accompanies stress induction of the anticancer metallodrug BOLD-100\/KP1339 in the endoplasmic reticulum. Angew Chem Int Ed Engl 60(10):5063\u20135068. https:\/\/doi.org\/10.1002\/anie.202015962","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"1540_CR24","first-page":"4573","volume":"30","author":"S Wang","year":"2010","unstructured":"Wang S, Zhang H, Cheng L, Evans C, Pan CX (2010) Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res 30(11):4573\u20134578","journal-title":"Anticancer Res"},{"key":"1540_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ab.2017.07.009","volume":"552","author":"LD Zorova","year":"2018","unstructured":"Zorova LD, Popkov VA, Plotnikov EY, Silachev DN, Pevzner IB, Jankauskas SS et al (2018) Mitochondrial membrane potential. Anal Biochem 552:50\u201359. https:\/\/doi.org\/10.1016\/j.ab.2017.07.009","journal-title":"Anal Biochem"},{"issue":"3","key":"1540_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/jat.1284","volume":"28","author":"NM Martins","year":"2008","unstructured":"Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC (2008) Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 28(3):337\u2013344. https:\/\/doi.org\/10.1002\/jat.1284","journal-title":"J Appl Toxicol"},{"issue":"12","key":"1540_CR27","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1248\/bpb.b19-00312","volume":"42","author":"A Inamura","year":"2019","unstructured":"Inamura A, Muraoka-Hirayama S, Sakurai K (2019) Loss of mitochondrial DNA by gemcitabine triggers mitophagy and cell death. Biol Pharm Bull 42(12):1977\u20131987. https:\/\/doi.org\/10.1248\/bpb.b19-00312","journal-title":"Biol Pharm Bull"},{"key":"1540_CR28","doi-asserted-by":"publisher","first-page":"111144","DOI":"10.1016\/j.biopha.2020.111144","volume":"134","author":"Z Liu","year":"2021","unstructured":"Liu Z, Fu Q, Wang Y, Cui L, Zhang W, Teng Y et al (2021) Synergy between vinorelbine and afatinib in the inhibition of non-small cell lung cancer progression by EGFR and p53 signaling pathways. Biomed Pharmacother 134:111144. https:\/\/doi.org\/10.1016\/j.biopha.2020.111144","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1540_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","volume":"8","author":"AE Pomeroy","year":"2022","unstructured":"Pomeroy AE, Schmidt EV, Sorger PK, Palmer AC (2022) Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer 8(11):915\u2013929. https:\/\/doi.org\/10.1016\/j.trecan.2022.06.009","journal-title":"Trends Cancer"},{"issue":"5\u20136","key":"1540_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.drup.2012.10.003","volume":"15","author":"JR Pritchard","year":"2012","unstructured":"Pritchard JR, Lauffenburger DA, Hemann MT (2012) Understanding resistance to combination chemotherapy. Drug Resist Updat 15(5\u20136):249\u2013257. https:\/\/doi.org\/10.1016\/j.drup.2012.10.003","journal-title":"Drug Resist Updat"},{"issue":"6","key":"1540_CR31","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.3892\/or.2015.4283","volume":"34","author":"Y Xu","year":"2015","unstructured":"Xu Y, Wang C, Su J, Xie Q, Ma L, Zeng L et al (2015) Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis. Oncol Rep 34(6):3051\u20133060. https:\/\/doi.org\/10.3892\/or.2015.4283","journal-title":"Oncol Rep"},{"issue":"1","key":"1540_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12906-024-04610-2","volume":"24","author":"T Pongking","year":"2024","unstructured":"Pongking T, Thongpon P, Intuyod K, Klungsaeng S, Thanan R, Chaidee A et al (2024) Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo. BMC Complement Med Ther 24(1):325. https:\/\/doi.org\/10.1186\/s12906-024-04610-2","journal-title":"BMC Complement Med Ther"},{"issue":"31","key":"1540_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s41048-019-0082-6","volume":"5","author":"C Luo","year":"2019","unstructured":"Luo C, Wang H, Liu Q (2019) A genetically encoded ratiometric calcium sensor enables quantitative measurement of the local calcium microdomain in the endoplasmic reticulum. Biophys Rep 5(31):42. https:\/\/doi.org\/10.1007\/s41048-019-0082-6","journal-title":"Biophys Rep"},{"issue":"51","key":"1540_CR34","doi-asserted-by":"publisher","first-page":"29698","DOI":"10.18632\/oncotarget.25679","volume":"9","author":"SJ Bakewell","year":"2018","unstructured":"Bakewell SJ, Rangel DF, Ha DP, Sethuraman J, Crouse R, Hadley E et al (2018) Suppression of stress induction of the 78-kilodalton glucose regulated protein (GRP78) in cancer by IT-139, an anti-tumor ruthenium small molecule inhibitor. Oncotarget 9(51):29698\u201329714. https:\/\/doi.org\/10.18632\/oncotarget.25679","journal-title":"Oncotarget"},{"issue":"14","key":"1540_CR35","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636\u20132644. https:\/\/doi.org\/10.1200\/JCO.2003.11.136","journal-title":"J Clin Oncol"},{"issue":"2","key":"1540_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK et al (2022) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 33(2):129\u2013142. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","journal-title":"Ann Oncol"},{"key":"1540_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/JEP.S267383","volume":"13","author":"PB Tchounwou","year":"2021","unstructured":"Tchounwou PB, Dasari S, Noubissi FK, Ray P, Kumar S (2021) Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J Exp Pharmacol 13:303\u2013328. https:\/\/doi.org\/10.2147\/JEP.S267383","journal-title":"J Exp Pharmacol"},{"issue":"1","key":"1540_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","volume":"78","author":"J Ciccolini","year":"2016","unstructured":"Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol 78(1):1\u201312. https:\/\/doi.org\/10.1007\/s00280-016-3003-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1540_CR39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2174\/138945012802009017","volume":"13","author":"A Capasso","year":"2012","unstructured":"Capasso A (2012) Vinorelbine in cancer therapy. Curr Drug Targets 13(8):1065\u20131071. https:\/\/doi.org\/10.2174\/138945012802009017","journal-title":"Curr Drug Targets"},{"issue":"3","key":"1540_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621\u2013681. https:\/\/doi.org\/10.1124\/pr.58.3.10","journal-title":"Pharmacol Rev"},{"issue":"6","key":"1540_CR41","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1046\/j.1523-1755.1998.00202.x","volume":"54","author":"E Healy","year":"1998","unstructured":"Healy E, Dempsey M, Lally C, Ryan MP (1998) Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 54(6):1955\u20131966. https:\/\/doi.org\/10.1046\/j.1523-1755.1998.00202.x","journal-title":"Kidney Int"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01540-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:07:42Z","timestamp":1753934862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01540-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}